Survivor Costs in Cost-Effectiveness Analysis

  1. Afschin Gandjour, MD, PhD
  1. From Institute of Health Economics and Clinical Epidemiology, University of Cologne, 50935 Köln, Germany.

    TO THE EDITOR:

    Golan and colleagues (1) present a cost-effectiveness analysis of several anti-Candida strategies for high-risk patients in the intensive care unit. They evaluate treatment effectiveness by the number of life-years that are gained …

    [Full Text of this Article]

    Related Article

    • Article:Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis
      • Yoav Golan,
      • Michael P. Wolf,
      • Stephen G. Pauker,
      • John B. Wong,
      • and Susan Hadley
      Ann Intern Med December 20, 2005 143:857-869
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med April 4, 2006 vol. 144 no. 7 534-535
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)
    4. Related Article

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 1, 2009, 151 (11)
    1. Alert me to current issues